Statistical analysis for rates of VGPR or better by CXCR4, TP53, TERT, and ARID1A mutational status in patients with WM with MYD88MUT
| . | Univariate analysis∗ . | Multivariate analysis† . | Multivariate analysis‡ . | |||
|---|---|---|---|---|---|---|
| Odds ratio (95% CI) . | P value . | Odds ratio (95% CI) . | P value . | Odds ratio (95% CI) . | P value . | |
| CXCR4MUT | 0.345 (0.156, 0.765) | .009 | 0.370 (0.160, 0.855) | .020 | - | - |
| CXCR4FS | 0.401 (0.143, 1.130) | .084 | - | - | 0.379 (0.130, 1.101) | .075 |
| CXCR4NS | 0.293 (0.096, 0.896) | .031 | - | - | 0.360 (0.112, 1.156) | .086 |
| TP53MUT | 0.653 (0.311, 1.368) | .259 | 0.780 (0.360, 1.690) | .529 | 0.781 (0.360, 1.692) | .530 |
| TERTMUT | 0.229 (0.051, 1.026) | .054 | 0.353 (0.075, 1.671) | .189 | 0.355 (0.075, 1.687) | .193 |
| . | Univariate analysis∗ . | Multivariate analysis† . | Multivariate analysis‡ . | |||
|---|---|---|---|---|---|---|
| Odds ratio (95% CI) . | P value . | Odds ratio (95% CI) . | P value . | Odds ratio (95% CI) . | P value . | |
| CXCR4MUT | 0.345 (0.156, 0.765) | .009 | 0.370 (0.160, 0.855) | .020 | - | - |
| CXCR4FS | 0.401 (0.143, 1.130) | .084 | - | - | 0.379 (0.130, 1.101) | .075 |
| CXCR4NS | 0.293 (0.096, 0.896) | .031 | - | - | 0.360 (0.112, 1.156) | .086 |
| TP53MUT | 0.653 (0.311, 1.368) | .259 | 0.780 (0.360, 1.690) | .529 | 0.781 (0.360, 1.692) | .530 |
| TERTMUT | 0.229 (0.051, 1.026) | .054 | 0.353 (0.075, 1.671) | .189 | 0.355 (0.075, 1.687) | .193 |
Patients with CXCR4MUT, TP53MUT, and TERTMUT trended toward lower VGPR + CR rate, lower MRR, and/or longer median time to response than patients with the respective WT alleles.
CI, confidence interval.
To compare the response rates, univariate logistic regression models were performed, and the odds ratio (95% CI) and the corresponding P values are shown.
Odds ratio (95% CI) and P values were estimated using a multivariate logistic regression model with treatment arm and CXCR4 (WT and MUT), TERT (WT and MUT), and TP53 (WT and MUT) mutational status as covariates to account for the correlations among the mutations and the treatment differences between treatment arms. WT is the reference group. The same models were performed to further compare the response rates between CXCR4WT and CXCR4NS or CXCR4FS (CXCR4 [WT, FS, and NS]).
MYD88 status was assessed by polymerase chain reaction–based assay, with a total of 190 patients with MYD88MUT WM.